Belgium-based clinical-stage biotechnology company Galapagos has announced the pricing for its proposed offering of American depository shares (ADS) to raise funds for its general corporate purposes, new and ongoing research and development (R&D) activities, and commercialisation.

Priced at $90 per ADS, the offering involves a total of 3.75 million shares that will raise gross proceeds of $337.5m for the company.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The offering is expected to be completed by 21 April.

US-based biopharmaceutical company Bristol-Myers Squibb Company (BMS) and Danish company Nordic Bioscience have signed a development agreement.

Under the agreement, the two companies will collaborate to develop translational biomarkers and diagnostics to evaluate non-alcoholic steatohepatitis (NASH) in pre-clinical models of fibrotic diseases and in clinical settings.

Clinical-stage biopharmaceutical company Zymeworks intends to raise between $58.5m and $72m in an initial public offering (IPO) of 4.5 million shares.

"US-based biopharmaceutical company Bristol-Myers Squibb Company (BMS) and Danish company Nordic Bioscience have signed a development agreement."

To be priced between $13 and $16 a share, the IPO also includes a 30-day option for underwriters to purchase up to an additional 657,000 shares to cover any over-allotment.

The Canadian company expects to receive net proceeds of $56.6m through the IPO.

US-based pharmaceutical company Evoke Pharma and clinical research organisation Spaulding Clinical Research have partnered to carry out the former’s planned comparative exposure pharmacokinetic (PK) trial for a product candidate named Gimoti.

The drug aims to treat the symptoms associated with acute and recurrent diabetic gastroparesis in adult women.

The clinical trial is expected to be completed in the second half of this year.

US-based biotechnology company Polaris Group intends to raise funds through a private placement of shares in order to replenish its working capital.

The placement will include up to 55 million shares of the company’s common stock.